Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)

Abstract

ABSTRACTBackground This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan.Methods We conducted a test-negative case-control study. We included medically attended episodes and hospitalizations involving individuals aged [Formula: see text]16 with signs and symptoms from July to November 2022, when Omicron BA.5 was dominant nationwide. To evaluate VE, we calculated adjusted ORs of vaccination among test-positive versus test-negative individuals using a mixed-effects logistic regression.Results For VE against symptomatic infections among individuals aged 16 to 59, VE of primary vaccination at > 180 days was 26.1% (95% CI: 10.6–38.8%); VE of the first booster was 58.5% (48.4–66.7%) at [Formula: see text]90 days, decreasing to 41.1% (29.5–50.8%) at 91 to 180 days. For individuals aged [Formula: see text]60, VE of the first booster was 42.8% (1.7–66.7%) at [Formula: see text]90 days, dropping to 15.4% (−25.9–43.2%) at 91 to 180 days, and then increasing to 44.0% (16.4–62.5%) after the second booster. For VE against severe diseases, VE of the first and second booster was 77.3% (61.2–86.7%) at [Formula: see text]90 days and 55.9% (23.4–74.6%) afterward.Conclusion mRNA booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.

Keywords

• BA.5
• COVID-19
• Japan
• SARS-CoV-2
• vaccine effectiveness
• monovalent